EGFR and urinary bladder cancer: PGRN was found to replace the typical ligand of EphA2-A1 in bladder cancer, phosphorylation of EphA2 Ser897 induced by PGRN binding to EphA2 might induce crosstalk between other receptor tyrosine kinases, including other Eph receptors and epidermal growth factor receptor (EGFR) [67].